TABLE 1.
Data analysis on patients’ clinical information.
| Group | |||
|---|---|---|---|
| Control | BC | ||
| Value | Value | ||
| Age* | 51.556 ± 12.334 | 54.637 ± 10.384 | |
| Menopause Status** | pre | 43 (42.16%) | |
| peri | 6 (5.88%) | ||
| post | 53 (51.96%) | ||
| Side** | left | 43 (42.16%) | |
| right | 55 (53.92%) | ||
| both | 4 (3.92%) | ||
| Cancer stage** | I | 24 (23.53%) | |
| II | 42 (41.18%) | ||
| III | 36 (35.29%) | ||
| ER_** | - | 7 (6.86%) | |
| + | 95 (93.14%) | ||
| PR_** | - | 14 (13.73%) | |
| + | 88 (86.27%) | ||
| Her2** | - | 69 (67.65%) | |
| borderline(2+)/intermediate | 13 (12.75%) | ||
| + | 20 (19.61%) | ||
| Sub type** | ER/PR+ Her2+ | 18 (17.65%) | |
| ER/PR+ Her2- | 65 (63.73%) | ||
| ER/PR- Her2+ | 2 (1.96%) | ||
| ER/PR- Her2- | 4 (3.92%) | ||
| Unknown | 13 (12.75%) | ||
| Cancer type** | Ductal | 92 (90.20%) | |
| Lobular | 8 (7.84%) | ||
| both | 2 (1.96%) | ||
BC, breast cancer; *mean ± standard deviation; **n (%).